METHOD FOR PREDICTION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN THERAPY OF DISSEMINATED GASTROINTESTINAL STROMAL TUMOURS WITH SUNITINIB Russian patent published in 2024 - IPC G01N33/68 G01N33/574 C12Q1/6827 C12Q1/6886 A61K31/404 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used to predict progression-free survival (PFS) and overall survival (OS) in treating disseminated gastrointestinal stromal tumours (GIST) with sunitinib. Before the beginning of the second line of GIST therapy with sunitinib, the tumour proliferation index Ki67 and the KIT gene status are determined. Combined predictor marker “KIT gene status + Ki67 tumour proliferation index” is determined. In case of “KIT gene mutation in exon 9 or absence of KIT gene mutation + tumour proliferation index Ki67<10%”, favourable prognosis of PFS and OS is determined. “KIT gene mutation in exon 11 + tumour proliferation index Ki67≥10%” shows an unfavourable prognosis.

EFFECT: method provides the most accurate prediction of PFS and OS during the therapy of disseminated GISTs with sunitinib by using a combined predictor marker.

1 cl, 3 ex